Minimal change disease medical therapy

Revision as of 16:20, 5 April 2015 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Minimal Change Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Minimal Change Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Immunohistology

Electron Microscopy

Electrocardiogram

X-ray

Echocardiorgaphy or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Minimal change disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Minimal change disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Minimal change disease medical therapy

CDC on Minimal change disease medical therapy

Minimal change disease medical therapy in the news

Blogs on Minimal change disease medical therapy

Directions to Hospitals Treating Minimal change disease

Risk calculators and risk factors for Minimal change disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, Serge Korjian

Overview

Pharmacologic therapy using corticosteroids is considered the mainstay of therapy for minimal change disease. According to the National Kidney Foundation (NKF) Kidney Disease – Improve Global Outcomes (KGIDO) guidelines in 2012,[1] initial empirical treatment using corticosteroids in patients presenting with nephrotic syndrome prior to a kidney biopsy is recommended. Notably also, the use of statins for hyperlipidemia and ACE-I or ARB for proteinuria are both not recommended in patients presenting with the initial episode of MCD.

Initial Therapy or Therapy for Infrequent Relapses[1]

Prednisone or Prednisolone

Prednisone and prednisolone are considered equivalent and may be used in same dosage.

  • Dose: Daily single dose of 1 mg/kg/d up to 80 mg /day or alternate-day single dose of 2 mg/kg/d up to 120 mg/day
  • Duration: 4 weeks, if tolerated. Treatment may continue up to 16 weeks to achieve remission, only if tolerated. Treatment should be tapered slowly over 6 months after achieving remission.

Relative contraindications of corticosteroids include uncontrolled diabetes mellitus, psychiatric diseases, and severe osteoporosis. In such cases, the use of alternative therapy is recommended.

Frequent Relapses or Steroid-Dependence[1]

Steroid dependence is defined as relapse during tapering of steroid therapy or within 4 weeks of steroid discontinuation.[2]

According to the National Kidney Foundation (NKF) Kidney Disease – Improve Global Outcomes (KGIDO) guidelines in 2012[1], cyclophosphamide is recommended. In case relapse occurs despite cyclophosphamide or fertility is a concern, cyclosporine or tacrolimus. Mycofenolate mofetil (MMF) may be used, but is often reserved as last option.[1]

Cyclophosphamide

  • Dose: 2-2.5 mg/kg/d
  • Duration: 8 weeks

Cyclophosphamide is contraindicated if fertility is a concern.

Cyclosporine

  • Dose: 3-5 mg/kg/d in divided doses
  • Duration: 1-2 years

Tacrolimus

  • Dose: 0.05-0.1 mg/kg/d in divided doses
  • Duration: 1-2 years

Mycophenolate Mofetil (MMF)

  • Dose: 500-1000 mg twice daily
  • Duration: 1-2 years

Contraindicated medications

Lipoid nephrosis is considered an absolute contraindication to the use of the following medications:

Steroid-Resistance

Steroid resistance is defined as the failure to reach remission despite the use of the above treatment options.[2] In such cases, FSGS must be highly considered and repeat renal biopsy is indicated.[1]

Acute Renal Failure

Patients with MCD complicated with acute renal failure are recommended to reinitiate corticosteroids (similar to regimen of initial therapy) and treated using the appropriate renal replacement therapy.[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH; et al. (2013). "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis". Am J Kidney Dis. 62 (3): 403–41. doi:10.1053/j.ajkd.2013.06.002. PMID 23871408.
  2. 2.0 2.1 Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G; et al. (2007). "Adult minimal-change disease: clinical characteristics, treatment, and outcomes". Clin J Am Soc Nephrol. 2 (3): 445–53. doi:10.2215/CJN.03531006. PMID 17699450.

Template:WH Template:WS